Table 1.

Current potential antiviral agents against SARS-CoV-2.

	Target	Antiviral agent	Type	Status	References
Viral entry	ACE2	HrsACE2	Recombinant protein	–	Monteil et al., 2020
	S protein	CR3022	Neutralizing antibody	–	Yuan et al., 2020
	Endocytosis	Umifenovir (Arbidol)	Membrane fusion inhibitor	Phase 4	Zumla et al., 2016; Sanders et al., 2020
	Endocytosis	EK1C4	Pan-coronavirus fusion inhibitor	–	Xia et al., 2020
	TMPRSS2	Camostat mesilate	Serine protease inhibitor	Phase 4	Hoffmann et al., 2020; Sanders et al., 2020
	TMPRSS2	Nafamostat	Serine protease inhibitor	Phase 2	Zumla et al., 2016; Bittmann et al., 2020
	TMPRSS2	Bromhexine hydrochloride	Mucolytic drug	–	Sonawane et al., 2020
	TMPRSS2	PAI-1	Serine protease inhibitor	–	Jankun, 2020
	Virus/Cell fusion	Chloroquine	Drug for autoimmune disease	Phase 4	Wang M. et al., 2020
Viral proteases	Mpro	Lopinavir/Ritonavir	Antiviral	Phase 4	Harrison, 2020; Sanders et al., 2020
	Mpro	Darunavir/covicistat	Antiviral	Phase 3
	Mpro	ASC09F/Oseltamivir	Antiviral	Phase 3	Lv et al., 2015; Zumla et al., 2016
	Mpro	Nelfinavir	Antiviral	–	Yamamoto et al., 2020
	Mpro	Baicalein	Antibacterial	–	Liu et al., 2020
	Mpro	a-ketoamide	Antiviral	–	Zhang et al., 2020b
	Mpro	Ebselen	Anti-inflammatory	–	Jin et al., 2020
	Mpro	Disulfiram	Drug for chronic alcoholism	-
	Mpro	Tideglusib	Kinase inhibitor	–
	Mpro	Carmofur	Anticancer	–
	Mpro	Shikonin	Natural product	–
	Mpro	PX-12	Anticancer	–
	Mpro	Compound 11a, 11b	Antiviral	–	Dai et al., 2020
Viral replication	RdRp	Remdesivir	Antiviral	Phase 3	Zumla et al., 2016; Sanders et al., 2020; Wang M. et al., 2020
	RdRp	Ribavirin	Antiviral	Phase 2
	RdRp	Favipiravir	Antiviral	Phase 4
	RdRp	Galidesivir	Antiviral	Phase 1	Elfiky, 2020
	RdRp	EIDD-1931	Antiviral	–	Sheahan et al., 2020
	RdRp	EIDD-2801	Antiviral	–
	RdRp	Tenofovir disoproxil	Antiviral	Phase 3	Elfiky, 2020